From Trial-and-Error to Process Control: Trailhead’s Approach to Human Cell Models
- Sirena Meade
- Jul 27
- 8 min read
Part 1 of a 3-part editorial series on Trailhead Biosystems
By Sirena Meade | Founder and Editor, The Biotech Beacon
For decades, drug discovery has depended on an imperfect translation: testing potential therapies in systems that are close enough to teach scientists something, but not always close enough to predict what will happen in a human body. Animal models have helped move medicine forward. They have shaped preclinical research, supported therapeutic development, and provided insight into disease biology long before a new therapy reaches human clinical trials. But animal biology is not human biology. A rat liver cell, a rodent neuron, or an engineered model system can offer useful information, but each comes with limitations when the ultimate question is how a human body will respond.
That gap, between animal models and humans, is becoming harder to ignore. In 2022, the FDA Modernization Act 2.0 removed the blanket statutory requirement that animal studies be used as part of the nonclinical testing package before human clinical trials. Then, in April 2025, the FDA announced a broader plan aimed at reducing animal testing requirements in certain areas by encouraging the use of New Approach Methodologies, or NAMs, including computational models, cell-based systems, and organoids. The shift does not eliminate animal testing entirely, nor does it mean new methods can bypass scientific validation. But it does point toward a future where human-relevant models play a larger role in drug discovery and development.
That future depends on a deceptively difficult question: where do the human cells needed for testing come from? For researchers building disease models, screening compounds, or studying toxicity, access to the right human cell type can shape the quality of the entire experiment. Traditional options all have tradeoffs. Established cell lines are widely used and relatively convenient, but they represent only a limited slice of human biology. Primary cells, which are isolated directly from human tissue, can be highly valuable, but supply is constrained. Some tissues are difficult or impossible to access from living donors. Cadaver-derived cells may be limited in quantity, affected by postmortem changes, and variable from donor to donor. Even when primary cells are available, batch-to-batch consistency can be difficult to achieve.
Induced pluripotent stem cells, or iPSCs, opened a different door in the mid-2000s. First demonstrated in mouse cells in 2006 and then in human cells in 2007, iPSC technology showed that adult cells could be reprogrammed back into a pluripotent state. Since then, scientists have been working to turn that discovery into practical tools for studying human biology.
In theory, iPSCs could help solve the cell supply problem. Instead of relying on scarce tissue samples, researchers could guide stem cells toward the specific cells they needed. iPSCs can theoretically become any cell type including neurons, endothelial cells, liver cells, cardiac cells, immune cells, and beyond.
However, in practice, the promise of stem cells has been much harder to realize. Stem cells are powerful precisely because they can become many things. The difficulty is getting them to become one specific thing, at the right level of maturity, with the right functional behavior, over and over again.
“The cells themselves have a mind of their own sometimes,” said Jennifer Antonchuk, Vice President of R&D at Trailhead Biosystems.
That is the central tension of stem cell differentiation. Biology does not behave like a simple chemical mixture. A protocol may depend on the timing, concentration, and order of growth factors, cytokines, small molecules, transcriptional cues, culture conditions, starting cell number, and the state of the cells themselves. Change one variable, and the outcome can shift. Change several at once, and the experimental space quickly becomes too large to explore using traditional methods.
Historically, much of differentiation protocol development has relied on published literature, internal expertise, and iterative optimization. Scientists test conditions, observe how the cells respond, and adjust. That work has built the foundation for today’s stem cell tools industry. Companies such as STEMCELL Technologies, FUJIFILM Cellular Dynamics, BrainXell, bit.bio, and others have helped expand the commercial landscape for stem cell research tools, iPSC-derived cells, differentiation media, and related products.
But the field still faces a bottleneck. Developing a new differentiated cell type can take over five years. Some desired cell types remain unavailable. Others exist but may be immature, heterogeneous, or insufficiently functional for the applications researchers need. A cell model cannot simply look right under a microscope. It has to behave like the cell it is meant to represent.
“They can’t just look like the cell type,” said David Llewellyn, CEO of Trailhead Biosystems. “They have to act like it too.”
That is where Trailhead’s story begins. Founded from science originating at Cleveland Clinic and Case Western Reserve University, Trailhead was built around a different way of thinking about differentiation. The company’s core bet is that stem cell differentiation does not have to remain a slow, one-variable-at-a-time biological guessing game. It can be treated as a process: measured, modeled, optimized, and eventually scaled.
Div Trivedi, now part of Trailhead’s leadership team as the COO, came to the company from an engineering, mathematics, and operations research background rather than a traditional biology path. That difference mattered. Early in the company’s formation, the team needed someone who could look at complex experimental data without bringing the same biological assumptions to it.
“They were seeking someone to analyze and model their data in as unbiased a way as possible,” he said.
What he saw was not only a biological challenge. It was a process-control challenge.
“We've built a platform that gives us the parameters to control a biological process,” Trivedi said.
That platform is now referred to as high-dimensional design of experiments, or HD-DoE®. In traditional differentiation development, scientists may test one factor at a time or optimize around protocols already described in the literature. Trailhead’s approach is designed to explore combinations of regulatory factors more systematically. Using high-throughput robotics, the company screens combinations of small molecules, cytokines, and other regulatory factors that influence differentiation. It then measures gene expression and applies mathematical modeling, bioinformatics, and machine learning to understand how those combinations affect cell fate.
In simpler terms, Trailhead is not only asking which ingredients matter. It is asking how those ingredients interact, when they matter, and how strongly they push a cell toward one fate over another. The goal is not simply to generate more data. It is to map the relationships between inputs and biological outcomes so the company can predict which combinations are most likely to drive the cells toward the desired identity.
Trailhead is also working to expand the platform’s capabilities through artificial intelligence. Because HD-DoE generates large, structured datasets showing how combinations of regulatory factors influence differentiation, the company sees AI as a way to further accelerate protocol development and improve prediction. Rather than relying only on public or observational biological datasets, Trailhead’s models can be informed by proprietary experimental data generated through its own platform. The goal is to make HD-DoE even more powerful over time by helping the company identify promising conditions faster, refine differentiation protocols more efficiently, and continue moving differentiated cell products closer to the biology researchers are trying to model.
According to Llewellyn, the compression created by the platform is substantial. “For every 1,000 experiments we do, we can mathematically extract results from the equivalent of doing 40,000 different conditions.”
That kind of compression matters because differentiation protocols are not quick experiments. Some can take weeks or months to run. If every condition must be tested manually and sequentially, protocol development becomes slow, expensive, and difficult to scale. Every failed condition costs time, material, and momentum. Trailhead’s HD-DoE platform is designed to shorten that path by allowing the company to search a wider experimental space and identify promising directions more efficiently.
The company says this approach can reduce development timelines that have historically taken five to ten years to less than two years for certain cell types. It also allows Trailhead to develop protocols internally rather than relying only on published materials and methods. That distinction is important. Trailhead is not positioning itself merely as another company selling differentiated cells. It is positioning itself as a platform company: one built around the ability to discover, optimize, and commercialize new differentiation protocols.
The output of that work still has to pass a biological test. Gene expression is a powerful readout, but it is not enough on its own. A cell that expresses the right markers may still fail to function like the intended cell type. During R&D, Trailhead characterizes cells across multiple dimensions, including gene expression, flow cytometry and antibody staining, morphology, and functional assays.
Antonchuk described morphology as one of the first checks. What do the cells look like? Do they have the shape, structure, or processes expected of that cell type? From there, the team looks at what proteins the cells express and whether they behave as expected. For neurons, that may include electrophysiology. For endothelial cells, it may include tube formation. For other cell types, it may mean testing whether the cells respond appropriately to known drugs or functional stimuli.
“The really fun stuff is, do they act like the cell should act?” Antonchuk said.
That question sits at the heart of the entire field. Human cell models are only useful if they are available, reproducible, mature, and functional. As drug discovery moves toward more human-relevant systems, the pressure will not simply be to make more cells. It will be to make better cells, with enough consistency that researchers can trust the data they generate.
Trailhead has now launched its first differentiated cell products and is building a broader pipeline of iPSC-derived cell types, media, kits, and related tools. Among the most anticipated examples is its A9 dopaminergic neuron program. A9 dopaminergic neurons are the neuronal subtype lost in Parkinson’s disease, making them highly relevant for disease modeling, target validation, drug screening, and potentially future therapeutic applications.
The broader opportunity is not limited to one cell type or one disease area. Trailhead’s leadership describes the company as entering a research-use human cell products market that is expanding alongside regulatory, scientific, and industry demand for better human models. In company materials, Trailhead cites estimates placing that market at around $6.6 billion today, with projected growth of up to $17 billion over the next decade as demand for human-relevant research models increases.
But the larger story is not only market size. It is the possibility that stem cell differentiation can become more predictable than it has been. Biology will never be simple. Cells are living systems; therefore they can be fragile, responsive, and complex. They vary from batch-to-batch and they are capable of resisting control.
Trailhead’s argument is not that biology can be stripped of that complexity. It is that complexity can be measured. Patterns can be modeled. Processes can be standardized. And if that is true, then the long-standing bottleneck in human cell model development may begin to shift, from trial-and-error to process control.
Trailhead is working to turn what has historically been scarce, variable, or difficult-to-access human biology into scalable human cell models. That is the problem the company is trying to solve. And it is the foundation for what comes next.
Key Takeaways
Trailhead Biosystems developed the HD-DoE® platform to improve control over stem cell differentiation.
The platform combines high-dimensional experimental design with computational modeling.
Better differentiated human cell models can improve drug discovery and disease research.
Trailhead is based in Cleveland, Ohio and is expanding commercialization of its technology.
Credits
Photography by Nicholas Campbell
Learn more:
About Trailhead Biosystems
Trailhead Biosystems is a Cleveland-based biotechnology company developing human cell models for drug discovery, disease research, and regenerative medicine. Its proprietary HD-DoE® platform combines high-dimensional experimental design, computational modeling, and biological validation to improve the reproducibility and control of stem cell differentiation. Learn more about Trailhead here: https://trailbio.com/.
About The Biotech Beacon
The Biotech Beacon is an independent publication dedicated to illuminating biotechnology, life sciences, and healthcare innovation across Ohio and the Midwest. Through in-depth reporting, founder interviews, and ecosystem analysis, it connects scientists, entrepreneurs, investors, and curious readers to the people and technologies shaping the future of healthcare.
Share Your Story
Every biotechnology company has a story worth telling. If your organization is developing innovative science, building new technologies, or advancing healthcare across Ohio and the Midwest, I'd love to learn more. Whether you're a startup, an established company, an incubator, or a research organization, if you're building something that deserves to be seen, from groundbreaking science to the people making it happen, I'd love to hear from you. Reach out at smeade@thebiotechbeacon.com or connect with me on LinkedIn.
Comments